Discover the first predictive therapy decision support tool

Our Story

OncoGenomX offers the first therapy decision support solution reflective of biology, clinical behavior, and pharmacological vulnerabilities of individual cancers to guide decisions on the composition of therapy regimen, combining the most effective drugs with the highest chance of conveying maximum clinical and health economic benefit.

We envision a future of AI and deep learning-enhanced therapy decision support, predicting which treatments are likely to work on the specific tumor of each individual patient – accurate, confident, tailor-made, and clinically actionable. Only therapy that hits a tumor’s biological weak points eliminates cancer effectively as a basis for prolonged life expectancy, if not curing it.

The current risk-adopted Breast Cancer therapy approach – intensive therapy for high-risk, moderate therapy for low-risk patients – is all but optimal and has a variety of undesirable consequences, including but not limited to frequently unprecise drug – tumor pairings, and treatment results that fall short of the pharmaceutically possible and of clinical expectations.

It has long been known that half of the women in Europe and the US newly diagnosed with Breast Cancer (750.000 every year) run the risk of overtreatment. Now study results¹ suggests that 50% of patients with advanced breast cancer are undertreated.

The same study¹ illustrates that accounting for the biological properties of individual cancers provides the opportunity of making a difference to patients.

Our Approach

Utilization of our service requires no additional invasive procedures and no additional diagnostic tests.

Patient data, personal or population-level, never leaves the hospital IT environment. Technology components fulfill governing quality requirements and Medical Device, Digital, and Cyber Laws.

A specifically trained system operator will ensure smooth processing and real-time delivery of analysis reports.

Selecting cancer therapy

When selecting cancer therapy regimens, oncologists worldwide lean towards the current treatment guidelines. However, the recommended treatment combinations are not equally suitable for each tumor and patient.

PredictionStar provides the granular information required to compose maximally efficacious treatment regimens as the rule, thus avoiding the costly consequences of suboptimal treatment prescriptions³.

1, https://seer.cancer.gov/statfacts/html/breast.html. 2, Mc Andrew & Finn, JCO Oncology Practice 2021, No. 18, 5, 319. 3, Study Report OGX-1019-HE003, OncogenomX, data on file.